Skip to main content

Table 2 Distribution of patients according to BMI, waist circumference percentiles, serum lipids, glucose percentiles and metabolic syndrome score

From: Second-generation antipsychotic medications and metabolic disturbance in children and adolescents

Characteristics

SGA (n = 72)

CTL (n = 79)

X2

P

BMI ≤ 85th n (%)

BMI ≥ 85th n (%)

23 (31.51)

49 (68.06)

70 (88.61)

9 (11.39)

51.12

 < 0.0001*

WC ≤ 90th n (%)

WC ≥ 90th n (%)

44 (61.11)

28 (38.89)

76 (96.20)

3 (3.80)

28.43

 < 0.0001*

Cholesterol ≤ 90th, n (%)

50 (69.44)

76 (96.20)

19.52

 < 0.0001

 < 0.0001

Cholesterol ≥ 90th, n (%)

22 (30.55)

3 (3.80)

LDL ≤ 90th, n (%)

LDL ≥ 90th, n (%)

47 (65.28)

25 (34.27)

75 (94.94)

4 (5.06)

21.35

HDL ≤ 50th, n (%)

HDL ≥ 50th, n (%)

69 (95.83)

3 (4.17)

55 (69.52)

24 (30.38)

17.36

 < 0.0001

TG ≤ 90th, n (%)

TG ≥ 90th, n (%)

35 (52.78)

37 (47.22)

74 (93.67)

5 (6.33)

38.09

 < 0.0001

FBS ≤ 99th, n (%)

FBS ≥ 99th, n (%)

56 (77.77)

16 (22.22)

77 (97.46)

2 (2.53)

13.91

0.0002

MtS < 3; n (%)

MtS ≥ 3; n (%)

30 (41.66)

42 (58.33)

78 (98.73)

1 (1.27)

60.23

 < 0.0001*

  1. *Significance P < 0.05
  2. CTL control, SGA second generation treated patients, n, number of patients per group; BMI body mass index, WC waist circumference, LDL low density lipoprotein, HDL high density lipoprotein, TG triglyceride, FBS fasting blood sugar, MtS metabolic syndrome
  3. X2, Chi-square; P value